Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma

Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma

Abstract Background The treatment of diffuse large B-cell lymphoma (DLBCL) is limited by the development of resistance to therapy, and there is a need to develop novel therapeutic strategies for relapsed and refractory aggressive lymphoma. Metformin is an oral agent for type 2 diabetes that has been...

Full description

Bibliographic Details
Main Authors: Anil R. Singh, Juan J. Gu, Qunling Zhang, Pallawi Torka, Suchitra Sundaram, Cory Mavis, Francisco J. Hernandez-Ilizaliturri
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Cancer & Metabolism
Subjects:
Metformin
Rituximab-chemotherapy resistance
Lymphoma
Glucose metabolism
Online Access:http://link.springer.com/article/10.1186/s40170-020-00213-w

Internet

http://link.springer.com/article/10.1186/s40170-020-00213-w

Similar Items